Medicines360 Announces Collaborative Research to Increase LARC Access in FQHCs

Federally Qualified Health Centers (FQHCs) are community-based providers that exist to meet patients where they live and provide the primary care services they need. With approximately 12,000 service delivery sites located across the country. FQHCs serve a large number of both insured and uninsured patients. FQHCs have sliding fee scales for uninsured patients to make care affordable and accessible.

As part of their mandate to provide primary care services, FQHCs deliver publicly funded family planning care to approximately 2 million women each year. However, these health centers can face unique challenges to offering long-acting reversible contraceptives (LARCs), meaning that not all FQHC patients have access to the full range of FDA-approved contraceptive methods.

Medicines360, with Waxman Strategies and Camber Collective, conducted research to identify these challenges through surveys and interviews with providers, administrators, and policy stakeholders between January 2019 and June 2019. Addressing these challenges would extend greater contraceptive choice to larger numbers of safety-net patients across the country.

In a white paper published this month, we provide the following recommendations:

  1. Provide targeted training and technical assistance. FQHCs should be given expanded access to clinical training and technical assistance on topics relating to family planning, including patient-centered counseling and services for LARC methods alongside the full range of FDA-approved contraceptive methods, consistent with national quality family planning (QFP) guidelines.
  2. Protect and expand grant programs and the use of evidence-based guidelines. On top of sustaining funding levels for Title X and Section 330, policymakers should consider safeguarding Title X’s evidence-based guidelines and clarify that FQHCs should provide affordable access to all 18 FDA-approved methods of contraception.
  3. Collect and report data on family planning care provided at FQHC sites. The federal government should collect, analyze, and report detailed data on the performance of FQHCs in the family planning context and measure their impact.
  4. Design optimal Medicaid reimbursement rates policies. Since Prospective Payment System (PPS) encounter rates are often too low to cover the cost of LARC-related care at FQHCs, policymakers should consider unbundling or “carving out” LARC product and service reimbursements from PPS rates.
  5. Reform state scope-of-practice and licensing laws. Although non-physician clinicians such as advanced practice registered nurses (APRNs) are trained in the provision of a range of services, various legal and reimbursement challenges may prevent them from helping to meet the need for family planning. State policymakers should consider removing barriers for non-physician clinicians.
  6. Enhance collaboration, training, and sharing of best practices. States should convene key family planning stakeholders into LARC learning collaboratives to establish referral systems, share resources, identify trainers, and share best practices on patient-centered counseling and services. These collaboratives should build on the insights of past efforts, such as the Increasing Access to Contraception Learning Community

To learn more about the research methodology, findings, policy recommendations, the full white paper is accessible here.

About Medicines360

Located in San Francisco, California, Medicines360 is a global nonprofit pharmaceutical organization with a mission to accelerate the timeline from health innovation to access for all women. Medicines360 is committed to working with healthcare providers, advocacy groups, and patients to deliver innovative and meaningful treatments that help women around the world have greater access to the medicines they need. For more information, visit

Share This

AVIBELA can be made available in the following 88 countries

  1. Algeria
  2. Angola
  3. Bangladesh
  4. Belize
  5. Benin
  6. Bhutan
  7. Botswana
  8. Burkina Faso
  9. Burundi
  10. Cambodia
  11. Cameroon
  12. Cape Verde
  13. Central African Republic
  14. Chad
  15. Comoros
  16. Costa Rica
  17. Cuba
  18. Democratic Republic of the Congo
  19. Djibouti
  20. Dominica
  21. Dominican Republic
  22. Egypt
  23. El Salvador
  24. Equatorial Guinea
  25. Eritrea
  26. Ethiopia
  27. Gabon
  28. Ghana
  29. Grenada
  30. Guatemala
  31. Guinea
  32. Guinea-Bissau
  33. Haiti
  34. Honduras
  35. India
  36. Indonesia
  37. Ivory Coast
  38. Jamaica
  39. Kenya
  40. Lao PDR
  41. Lesotho
  42. Liberia
  43. Libya
  44. Madagascar
  45. Malawi
  46. Malaysia
  47. Maldives
  48. Mali
  49. Mauritania
  50. Mauritius
  51. Mayotte
  52. Morocco
  53. Mozambique
  54. Myanmar
  55. Namibia
  56. Nepal
  57. Nicaragua
  58. Niger
  59. Nigeria
  60. Pakistan
  61. Panama
  62. Papua New Guinea
  63. Philippines
  64. Republic of the Congo
  65. Rwanda
  66. Sao Tome and Principe
  67. Senegal
  68. Seychelles
  69. Sierra Leone
  70. Somalia
  71. South Africa
  72. South Sudan
  73. Sri Lanka
  74. Kitts and Nevis
  75. Lucia
  76. Vincent & the Grenadines
  77. Sudan
  78. Swaziland
  79. Tanzania
  80. Thailand
  81. The Gambia
  82. Timor-Leste
  83. Togo
  84. Tunisia
  85. Uganda
  86. Vietnam
  87. Zambia
  88. Sri Lanka

Tina Raine-Bennett, MD, MPH, FACOG

Chief Executive Officer

Tina Raine-Bennett, MD, MPH, is CEO of Medicines360. Previously, she served as a senior research scientist at the Kaiser Permanente Northern California Division of Research and the research director of the Women’s Health Research Institute. She is a Board-Certified Obstetrician Gynecologist who received her medical training at the University of California, San Diego, and post-graduate residency training and MPH at the University of Washington in Seattle, where she also completed a Robert Wood Johnson Clinical Scholars Fellowship. She was also senior staff physician at Kaiser Permanente and has a special interest in family planning and adolescent reproductive health.

As the director of the Women’s Health Research Institute, Dr. Raine-Bennett focused on expanding research on women’s health within the Division and translating women’s health research into clinical practice and policy within the Ob/Gyn departments in Northern California. She also promoted the involvement of clinicians in research designed to improve the health outcomes and healthcare experiences of women at Kaiser Permanente and women in general.

Prior to Kaiser Permanente, Dr. Raine-Bennett was a professor in the Department of Obstetrics, Gynecology, and Reproductive Sciences at University of California, San Francisco (UCSF). She was based at San Francisco General Hospital where she was also the medical director of the New Generation Health Center, a UCSF affiliate site that provides community-based reproductive health services. Dr. Raine-Bennett’s research has focused on contraceptive methods and on elucidating factors that influence contraceptive choice and continuation, and she was principal investigator on NIH grants to assess hormonal contraceptive use predictors and develop interventions to improve contraceptive access.

Her past and current research on emergency contraception has focused on the safety of making emergency contraception more accessible and she conducted a pivotal clinical trial to make emergency contraception available to teens without a prescription. She served on the editorial board of Obstetrics and Gynecology and has over 100 peer-reviewed publications. She was the Treasurer of the Board of Directors for the Society of Family Planning and Society of Family Planning Research Fund. She has also served as an examiner for the American Board of Obstetrics and Gynecology, and on national committees for the American College of Obstetrics and Gynecology and the National Medical Board of Planned Parenthood Federation of America.